LIXT: the balance sheet

MyFinsight

For the year ending 2025-12-31, LIXT has $12,733,621 in assets. $1,772,070 in debts.

Balance Sheets	2025-12-31
Cash	5,106,872
Prepaid insurance	26,682
Other prepaid expenses	44,825
Total current assets	5,178,379
Light proton therapy system equipment	6,582,560
Right-of-use lease assets	972,682
Total assets	12,733,621

Related parties accounts payable and accrued expenses	436,482
Research and development contract liabilities	232,138
Operating lease obligations, current	595,418
Series b convertible preferred stock 8 cumulative dividend payable	69,073
Total current liabilities	1,333,111
Operating lease obligations, long-term	438,959
Total liabilities	1,772,070
Preferred stock, value	1,731,569
Common stock, 0.0001 par value authorized 100,000,000 shares issued and outstanding 8,790,102 and 2,249,290 shares at december 31, 2025 and 2024, respectively	879
Additional paid-in capital	66,008,824
Accumulated deficit	-58,077,213
Total lixte biotechnology stockholders equity	9,664,059
Non-controlling interest	1,297,492
Total stockholders equity	10,961,551
Total liabilities and stockholders equity	12,733,621

Unit: Dollar.